Disrupted fat distribution and composition due to medium-chain triglycerides in mice with a β-oxidation defect

American Journal of Clinical Nutrition

Volumn 94, Issue 2, 2011, Pages 439-449

  Tucci, Sara ^a   Flog̈el, Ulrich ^b   Sturm, Marga ^a   Borsch, Elena ^b   Spiekerkoetter, Ute ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; MEDIUM CHAIN TRIACYLGLYCEROL; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL;

ABDOMINAL FAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT DISTRIBUTION; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; ENZYME DEFICIENCY; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; HISTOPATHOLOGY; INTRAABDOMINAL FAT; LIPID METABOLISM; LIPID STORAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTON NUCLEAR MAGNETIC RESONANCE; VERY LONG ACYL COENZYME A DEHYDROGENASE DEFICIENCY;

ACYL-COA DEHYDROGENASE, LONG-CHAIN; ANIMALS; BODY COMPOSITION; BODY FAT DISTRIBUTION; FATTY ACIDS, NONESTERIFIED; LIPID METABOLISM; LIVER; METABOLISM, INBORN ERRORS; MICE; MICE, INBRED C57BL; MITOCHONDRIAL DISEASES; MUSCULAR DISEASES; OXIDATION-REDUCTION; OXIDATIVE STRESS; TRIGLYCERIDES;

MUS;

EID: 79960858676     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.111.012948     Document Type: Article

References (53)

1. Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003;348:2304-12. (Pubitemid 36638104)
2. Spiekerkoetter U, Tokunaga C, Wendel U, et al. Changes in blood carnitine and acylcarnitine profiles of very long-chain acyl-CoA de-hydrogenase-deficient mice subjected to stress. Eur J Clin Invest 2004; 34:191-6. (Pubitemid 38406633)
3. Arnold GL, Van HJ, Freedenberg D, et al. A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 2009;96:85-90.
4. Gregersen N, Andresen BS, Corydon MJ, et al. Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Hum Mutat 2001;18:169-89. (Pubitemid 32807897)
5. Spiekerkoetter U. Mitochondrial fatty acid oxidation disorders: clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening. J Inherit Metab Dis 2010;33:527-32.
6. Kompare M, Rizzo WB. Mitochondrial fatty-acid oxidation disorders. Semin Pediatr Neurol 2008;15:140-9.
7. Orngreen MC, Norgaard MG, Sacchetti M, van Engelen BG, Vissing J. Fuel utilization in patients with very long-chain acyl-CoA dehydrogenase deficiency. Ann Neurol 2004;56:279-83.
8. Spiekerkoetter U, Lindner M, Santer R et al. Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis 2009;32 :498-505.
9. Spiekerkoetter U, Lindner M, Santer R, et al. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis 2009;32:488-97.
10. Gillingham MB, Scott B, Elliott D, Harding CO. Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab 2006;89:58-63. (Pubitemid 44205484)
11. Roe CR, Sweetman L, Roe DS, David F, Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 2002; 110:259-69. (Pubitemid 34787363)
12. Primassin S, Tucci S, Herebian D, et al. Pre-exercise medium-chain triglyceride application prevents acylcarnitine accumulation in skeletal muscle from very-long-chain acyl-CoA-dehydrogenase-deficient mice. J Inherit Metab Dis 2010;33:237-46.
13. Tucci S, Primassin S, Ter VF, Spiekerkoetter U. Medium-chain triglycerides impair lipid metabolism and induce hepatic steatosis in very long-chain acyl-CoA dehydrogenase (VLCAD)-deficient mice. Mol Genet Metab 2010;101:40-7.
14. Spiekerkoetter U, Sun B, Zytkovicz T, Wanders R, Strauss AW, Wendel U. MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency. J Pediatr 2003;143:335-42. (Pubitemid 37188318)
15. Spiekerkoetter U, Tokunaga C, Wendel U, et al. Tissue carnitine homeostasis in very-long-chain acyl-CoA dehydrogenase-deficient mice. Pediatr Res 2005;57:760-4. (Pubitemid 40727102)
16. Spiekerkoetter U, Ruiter J, Tokunaga C, et al. Evidence for impaired gluconeogenesis in very long-chain acyl-CoA dehydrogenase-deficient mice. Horm Metab Res 2006;38:625-30. (Pubitemid 44759212)
17. Exil VJ, Roberts RL, Sims H, et al. Very-long-chain acyl-coenzyme a dehydrogenase deficiency in mice. Circ Res 2003;93:448-55. (Pubitemid 37100010)
18. Kunnecke B, Verry P, Bénardeau A, von Kienlin M. Quantitative body composition analysis in awake mice and rats by magnetic resonance relaxometry. Obes Res 2004;12:1604-15. (Pubitemid 41132469)
19. Moonen CT, Dimand RJ, Cox KL. The noninvasive determination of linoleic acid content of human adipose tissue by natural abundance carbon-13 nuclear magnetic resonance. Magn Reson Med 1988;6:140-57. (Pubitemid 18066054)
20. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74. (Pubitemid 29420675)
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
22. Lawrence RA, Burk RF. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 1976;71:952-8.
23. Mantha SV, Prasad M, Kalra J, Prasad K. Antioxidant enzymes in hypercholesterolemia and effects of vitamin E in rabbits. Atherosclerosis 1993;101:135-44. (Pubitemid 23214226)
24. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976;15:212-6.
25. Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med 2002;40:718-24.
26. Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 5. Reference procedure for the measurement of catalytic concentration of aspartate aminotransferase. Clin Chem Lab Med 2002;40:725-33.
27. Schafer C, Hoffmann L, Heldt K, et al. Osmotic regulation of betaine homocysteine-S-methyltransferase expression in H4IIE rat hepatoma cells. Am J Physiol Gastrointest Liver Physiol 2007;292:G1089-98. (Pubitemid 46557778)
28. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002;65:166-76. (Pubitemid 34121108)
29. Ntambi JM. The regulation of stearoyl-CoA desaturase (SCD). Prog Lipid Res 1995;34:139-50.
30. Swift LL, Hill JO, Peters JC, Greene HL. Medium-chain fatty acids: evidence for incorporation into chylomicron triglycerides in humans. Am J Clin Nutr 1990;52:834-6.
31. Guo W, Xie W, Han J. Modulation of adipocyte lipogenesis by octanoate: involvement of reactive oxygen species. Nutr Metab (Lond) 2006;3:30.
32. Guillot E, Vaugelade P, Lemarchal P, Rerat A. Intestinal absorption and liver uptake of medium-chain fatty acids in non-anaesthetized pigs. Br J Nutr 1993;69:431-42. (Pubitemid 23105481)
33. Turner N, Hariharan K, TidAng J, et al. Enhancement of muscle mitochondrial oxidative capacity and alterations in insulin action are lipid species dependent: potent tissue-specific effects of medium-chain fatty acids. Diabetes 2009;58:2547-54.
34. Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996;24:200-8. (Pubitemid 26059117)
35. Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2002;282:G193-9. (Pubitemid 34651674)
36. Bergman RN, Kim SP, Catalano KJ, et al. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity (Silver Spring) 2006; 14(suppl 1):16S-9S.
37. Mathew M, Tay E, Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol 2010;9:9.
38. Phillips LK, Prins JB. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep 2008;10:156-64.
39. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83(suppl):1505S-19S. (Pubitemid 44713092)
40. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008;197:12-24.
41. Massaro M, Scoditti E, Carluccio MA, De CR. Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease. Prostaglandins Leukot Essent Fatty Acids 2008;79:109-15.
42. Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 2004;6:461-7. (Pubitemid 39585671)
43. Fessler MB, Rudel LL, Brown JM. Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Curr Opin Lipidol 2009;20:379-85.
44. Nakamura MT, Cheon Y, Li Y, Nara TY. Mechanisms of regulation of gene expression by fatty acids. Lipids 2004;39:1077-83. (Pubitemid 40129050)
45. Alkhateeb H, Chabowski A, Glatz JF, Luiken JF, Bonen A. Two phases of palmitate-induced insulin resistance in skeletal muscle: impaired GLUT4 translocation is followed by a reduced GLUT4 intrinsic activity. Am J Physiol Endocrinol Metab 2007;293:E783-93. (Pubitemid 47358991)
46. Reynoso R, Salgado LM, Calderon V. High levels of palmitic acid lead to insulin resistance due to changes in the level of phosphorylation of the insulin receptor and insulin receptor substrate-1. Mol Cell Biochem 2003;246:155-62. (Pubitemid 36798736)
47. Riserus U. Fatty acids and insulin sensitivity. Curr Opin Clin Nutr Metab Care 2008;11:100-5. (Pubitemid 351323169)
48. Vessby B, Gustafsson IB, Tengblad S, Boberg M, Andersson A. Desaturation and elongation of fatty acids and insulin action. Ann N Y Acad Sci 2002;967:183-95. (Pubitemid 34721905)
49. Nagao K, Yanagita T. Medium-chain fatty acids: functional lipids for the prevention and treatment of the metabolic syndrome. Pharmacol Res 2010;61:208-12.
50. Hill JO, Peters JC, Swift LL, et al. Changes in blood lipids during six days of overfeeding with medium or long chain triglycerides. J Lipid Res 1990;31:407-16. (Pubitemid 20107981)
51. Beverley D, Arthur R. Fatty liver and medium chain triglyceride (MCT) diet. Arch Dis Child 1988;63:840-2.
52. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010;52:774-88.
53. Schattenberg JM, Galle PR. Animal models of non-alcoholic steatohepatitis: of mice and man. Dig Dis 2010;28:247-54.